Findings From an Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia (AML), Including AML-M4 and AML-M5, Treated With Venetoclax (Ven) Plus Azacitidine (Aza)

被引：0
|
作者：
Konopleva, Marina [1 ]
DiNardo, Courtney [2 ]
Sun, Yan [3 ]
Loghavi, Sanam [2 ]
Jung, Paul [3 ]
Potluri, Jalaja [3 ]
Dail, Monique [4 ,5 ]
Chyla, Brenda [3 ]
Pollyea, Daniel
机构：
[1] Montefiore Einstein Canc Ctr, New York, NY USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] Univ Colorado, Sch Med, Aurora, CO USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
acute myeloid leukemia; monocytic; venetoclax; azacitidine;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-095
引用
收藏
页码：S266 / S267
页数：2
相关论文
共 50 条
  • [21] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    Jaddaoui, Samiha
    Bencharef, Hanaa
    Addakiri, Sara
    Dehbi, Hind
    Lamchahab, Mouna
    Quessar, Asmaa
    Madani, Abdellah
    Oukkache, Bouchra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S256
  • [22] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Konopleva, Marina
    Maiti, Abhishek
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Loghavi, Sanam
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Golez, Michelle
    Pierce, Sherry A.
    Nogueras Gonzalez, Graciela M.
    Ning, Jing
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2021, 138
  • [23] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    Zeidan, Amer M.
    Westermann, Joerg
    Kovacsovics, Tibor
    Assouline, Sarit
    Schuh, Andre C.
    Kim, Hee-Je
    Macias, Gabriela Rodriguez
    Sanford, David
    Luskin, Marlise R.
    Stein, Eytan M.
    Malek, Kamel
    Lyu, Jiaying
    Stegert, Mario
    Esteve, Jordi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S255 - S255
  • [24] Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine
    Maiti, Abhishek
    Konoplev, Sergej
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Ravandi, Farhad
    Daver, Naval
    Pemmaraju, Naveen
    Borthakur, Gautam
    Bose, Prithviraj
    Issa, Ghayas C.
    Short, Nicholas J.
    Yilmaz, Musa
    Alvarado, Yesid
    Ferrajoli, Alessandra
    Jabbour, Elias
    Jain, Nitin
    Ohanian, Maro
    Takahashi, Koichi
    Thompson, Philip A.
    Rausch, Caitlin R.
    Montalbano, Kathryn
    Pierce, Sherry A.
    Patel, Keyur P.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Konopleva, Marina
    BLOOD, 2020, 136
  • [25] Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies
    Pollyea, Daniel A.
    Stevens, Brett M.
    Winters, Amanda
    Minhajuddin, Mohd
    Gutman, Jonathan A.
    Purev, Enkhtsetseg
    Smith, Clayton
    Abbott, Diana
    Jordan, Craig T.
    BLOOD, 2017, 130
  • [26] Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML)
    Garcia-Manero, Guillermo
    Goldberg, Aaron D.
    Winer, Eric S.
    Altman, Jessica K.
    Fathi, Amir T.
    Odenike, Olatoyosi
    Roboz, Gail J.
    Gallacher, Phillip
    Wennborg, Anders
    Hickman, Denice Kaylor
    Attar, Eyal C.
    Sallman, David A.
    BLOOD, 2021, 138
  • [27] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
    Daver, Naval
    Senapati, Jayastu
    Maiti, Abhishek
    Loghavi, Sanam
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jabbour, Elias
    Montalban-Bravo, Guillermo
    Tang, Guilin
    Sasaki, Koji
    Borthakur, Gautam
    Yilmaz, Musa
    Alvarez, Joie
    Pierce, Sherry A.
    Gonzalez, Graciela M. Nogueras
    Ning, Jing
    Issa, Ghayas C.
    Andreeff, Michael
    Abbas, Hussein A.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2022, 140
  • [28] Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study.
    Daver, Naval Guastad
    Stevens, Don A.
    Hou, Jing-Zhou
    Yamauchi, Takahiro
    Moshe, Yakir
    Fong, Chun Yew
    Marzocchetti, Angela
    Adamec, Ryan
    Patel, Maulik
    Lambert, Stacie
    Wu, Kevin
    Rollig, Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR LOW-DOSE CYTARABINE (LDAC) IN THE AZA-AML-001 STUDY
    Seymour, J. F.
    Doehner, H.
    Kumar, R.
    Stone, R. M.
    Wierzbowska, A.
    Bernal del Castillo, T.
    Falantes, J.
    Delaunay, J.
    Sabloff, M.
    Voso, M. T.
    Kim, I.
    Ram, R.
    Gau, J. P.
    Songer, S.
    Lucy, L. M.
    Beach, C.
    Dombret, H.
    HAEMATOLOGICA, 2015, 100 : 381 - 381
  • [30] Early response to therapy with 5-azacitidine and venetoclax in three transplant-ineligible patients with acute myeloid leukemia (AML)
    Steiner, L.
    Jawhar, M.
    Fabarius, A.
    Nowak, D.
    Hofmann, W. - K.
    Metzgeroth, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 203 - 203
12345